about
Impulsive delayed reward discounting as a genetically-influenced target for drug abuse prevention: a critical evaluationPharmacotherapy for attention-deficit/hyperactivity disorder: from cells to circuits.The Association of SNAP25 Gene Polymorphisms in Attention Deficit/Hyperactivity Disorder: a Systematic Review and Meta-Analysis.Atomoxetine modulates spontaneous and sensory-evoked discharge of locus coeruleus noradrenergic neurons.Histamine H3 receptor antagonists/inverse agonists on cognitive and motor processes: relevance to Alzheimer's disease, ADHD, schizophrenia, and drug abuseAcute administration of methylphenidate alters the prefrontal cortex neuronal activity in a dose-response characteristic.Attention-deficit/hyperactivity disorder (ADHD) and high risk behaviorsThe effects of stimulant medication on working memory functional connectivity in attention-deficit/hyperactivity disorder.Neural correlates of inhibitory control and functional genetic variation in the dopamine D4 receptor geneAttention-deficit hyperactivity disorder (ADHD) stimulant medications as cognitive enhancersLong-term neurocognitive effects of methylphenidate in patients with attention deficit hyperactivity disorder, even at drug-free statusStereochemistry and neuropharmacology of a 'bath salt' cathinone: S-enantiomer of mephedrone reduces cocaine-induced reward and withdrawal in invertebrates.Nucleus accumbens neuronal activity in freely behaving rats is modulated following acute and chronic methylphenidate administration.Abnormal functional connectivity in children with attention-deficit/hyperactivity disorder.Advanced Test of Attention in Children with Attention-Deficit/Hyperactivity Disorder in Japan for Evaluation of Methylphenidate and Atomoxetine EffectsStress-induced cognitive dysfunction: hormone-neurotransmitter interactions in the prefrontal cortexVariable maternal stress in rats alters locomotor activity, social behavior, and recognition memory in the adult offspring.Methylphenidate and atomoxetine enhance sensory-evoked neuronal activity in the visual thalamus of male rats.Attention deficit hyperactivity disorder and athletes.Neurocognitive phenomics: examining the genetic basis of cognitive abilities.Bupropion for attention deficit hyperactivity disorder (ADHD) in adults.The 5 choice continuous performance test (5C-CPT): A novel tool to assess cognitive control across species.Hyperactivity and impaired attention in Gamma aminobutyric acid transporter subtype 1 gene knockout mice.Effects of methylphenidate on basic and higher-order oculomotor functions.Effects of intra-accumbal administration of dopamine and ionotropic glutamate receptor drugs on delay discounting performance in rats.Differential long-term medication impact on executive function and delay aversion in ADHD.Atomoxetine accelerates attentional set shifting without affecting learning rate in the rat.
P2860
Q26782950-D0387280-8E95-4B0B-97A2-70463299085FQ27687469-992D948C-C6C1-4BEF-8F18-64F30804B147Q30251841-40277EA0-5E32-4D2B-8978-2BD4476AF241Q30445190-9E8D1D6F-3547-4F83-93E7-9861E93F9A5AQ30462161-709212A5-A4D8-43E2-B08E-CB58414B4BD6Q33679327-38FCDAEC-545A-4357-8499-0C7FE99D9A62Q33803515-EEF42983-1693-4FD4-B902-50904A9A5992Q33995574-EEA00FDA-0D91-4259-B1FC-F79BF73EEE18Q34267222-9C67BEFD-4D8A-4946-A9A7-75380FA17A9AQ34349991-65A2AB6E-CED7-4E1B-BBEF-6599633AFD02Q34472512-0FA47A8F-B924-4F7F-8E47-E663C08FB63DQ35566736-692EEBC3-BF05-40F5-9B3B-D7A2FD62715CQ35809600-1CCB945B-FA97-41B4-BB2E-41456BE60218Q36343155-F50D13DC-ADC9-4D7C-972A-22BFA559300AQ36514345-827736AE-798E-452E-B5E1-CE61FFA88A20Q36742509-9832123A-289E-42CC-9106-9A84CCC84D5DQ36925903-C144E935-9440-4BA7-8D3E-00C6508E0CBCQ37451932-B78EA586-D872-4DFD-8F8A-2F30EE27BA95Q37596910-BE3625C7-E351-4859-8D34-4680972D565DQ38063594-E0A24FB8-AEF4-46A4-B877-C646B9605200Q43075919-5102F037-4CA2-4AE1-ADAF-E047AA0B532AQ46014866-3F7DDDFB-5A9A-4C21-9C78-6375A98EA843Q47685099-621FF795-472F-4756-BFEE-325AEB07443FQ48511523-13CD918B-E88D-415C-8545-6A7829F6569CQ49683743-7A18CC63-3EC7-46DB-B5C3-543E4C9B8716Q49821724-762972A6-5A25-48FD-A00D-853A83D0D220Q50576520-E2751B37-E296-4102-8CB5-37EEF7759EF3
P2860
description
2011 nî lūn-bûn
@nan
2011 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Cognitive enhancers for the treatment of ADHD
@ast
Cognitive enhancers for the treatment of ADHD
@en
Cognitive enhancers for the treatment of ADHD
@en-gb
Cognitive enhancers for the treatment of ADHD
@nl
type
label
Cognitive enhancers for the treatment of ADHD
@ast
Cognitive enhancers for the treatment of ADHD
@en
Cognitive enhancers for the treatment of ADHD
@en-gb
Cognitive enhancers for the treatment of ADHD
@nl
prefLabel
Cognitive enhancers for the treatment of ADHD
@ast
Cognitive enhancers for the treatment of ADHD
@en
Cognitive enhancers for the treatment of ADHD
@en-gb
Cognitive enhancers for the treatment of ADHD
@nl
P2093
P2860
P1476
Cognitive enhancers for the treatment of ADHD
@en
P2093
F Joseph McClernon
L Cinnamon Bidwell
Scott H Kollins
P2860
P304
P356
10.1016/J.PBB.2011.05.002
P407
P577
2011-08-01T00:00:00Z